Factor VIII Inhibitor Profile, Professional Interpretation
Use
The test is used for interpreting the detection of the presence and titer of a specific factor inhibitor directed against coagulation Factor VIII (FVIII). These inhibitors are IgG antibodies that typically result in potentially life-threatening hemorrhage. The test is beneficial for multiple patient populations, such as patients with congenital FVIII deficiency (hemophilia A) in response to therapeutic infusions of factor VIII concentrate, older nonhemophiliac adults, postpartum women, and patients with other autoimmune illnesses.
Special Instructions
The test is not directly orderable and is only available as a reflex under specific conditions. It is linked to a comprehensive evaluation for Factor VIII inhibitors (referenced as 8INHE / Factor VIII Inhibitor Evaluation, Plasma). An interpretive report is issued by a coagulation expert, who reviews the laboratory data.
Limitations
The test does not present any significant cautionary statements regarding improper handling or specimen problems. However, it is important to follow proper specimen collection and handling protocols to avoid diagnostic confusion. No significant interfering substances are noted that could impact the test results interpretation.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 69049-5
- 69049-5
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
Na Cit
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |